Last reviewed · How we verify

GnRHa with Tamoxifen — Competitive Intelligence Brief

GnRHa with Tamoxifen (GnRHa with Tamoxifen) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: GnRH agonist + selective estrogen receptor modulator (SERM) combination. Area: Oncology.

phase 3 GnRH agonist + selective estrogen receptor modulator (SERM) combination GnRH receptor (GnRHR) and estrogen receptor (ER) Oncology Small molecule Live · refreshed every 30 min

Target snapshot

GnRHa with Tamoxifen (GnRHa with Tamoxifen) — Asan Medical Center. GnRHa suppresses estrogen production while tamoxifen blocks estrogen receptor signaling, providing dual hormonal inhibition for hormone-sensitive breast cancer.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
GnRHa with Tamoxifen TARGET GnRHa with Tamoxifen Asan Medical Center phase 3 GnRH agonist + selective estrogen receptor modulator (SERM) combination GnRH receptor (GnRHR) and estrogen receptor (ER)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (GnRH agonist + selective estrogen receptor modulator (SERM) combination class)

  1. Asan Medical Center · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). GnRHa with Tamoxifen — Competitive Intelligence Brief. https://druglandscape.com/ci/gnrha-with-tamoxifen. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: